Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]
Barclays announced expanded coverage on seven biotech stocks Wednesday. Below are the new ratings and price targets along with comments from analyst Geoff Meacham.Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) was rated at Underweight with an $8 price target. The firm’s thesis was that “Achillion is likely to get left behind even with solid clinical data; a takeout may be one of […]
View photo.Deutsche Bank on Thursday named its top Small-Cap Biotech picks for 2015. The top picks were selected because they were either a disruptive technology, a rare or orphan disease market, an unmet need market or a stock with a big-time catalyst.Here is what to watch for in Deutsche’s top picks.
PTC Therapeutics, Inc. (NASDAQ: PTCT)
Deutsche highlighted PTC Therapeutics as its […]
View gallery.A recent report by Morgan Stanley predicts a greater than 40 percent growth in the Hepatitis C (HCV) market in 2015. Projections indicate that the HCV market could be worth $15 billion in upcoming years, with two-thirds of treatment occurring in the United States.
HCV Forerunners Gilead And AbbVie
Morgan Stanley projects that Gilead Sciences, Inc.’s (NASDAQ: GILD) Harvoni and Sovaldi […]
